ARC Program Leader Elizabeth Hart, MD, explains how advances in disease biology, innovative evidence strategies, and greater flexibility in trial design could bring safer and more effective treatments to patients.
By Angie Drakulich | November 2, 2026
The US Food and Drug Administration’s Accelerating Rare disease Cures (ARC) Program released its latest annual report last month, focused on its 2025-2030 strategic plan goals and developments to date. The program was established in 2022 to speed and increase the development of safe and effective treatments for people living with rare diseases.
Here, ARC Program leader Elizabeth Hart, MD, talks to BionewsHCP Editor Angie Drakulich about the program’s progress, how advances in rare disease science are shaping regulatory approaches, and how the research and development field can overcome barriers in clinical trial design and evidence generation to accelerate the development of new treatments for rare diseases. Dr. Hart serves as the Associate Director for Rare Diseases within the Office of New Drugs (OND) at FDA’s Center for Drug Evaluation and Research (CDER).
Elizabeth Hart, MD
Associate Director for Rare Diseases
Office of New Drugs (OND)
FDA’s Center for Drug Evaluation and Research (CDER)
BionewsHCP: ARC’s 2025-2030 Strategic Plan establishes core goals for scientific and regulatory innovation, engagement and education, and operations. What are the most important outcomes you hope the plan will deliver for rare disease drug development?
Dr. Hart: The strategic plan strives to facilitate ARC’s vision of speeding and increasing the development of effective and safe treatment options addressing the unmet needs of patients with rare diseases. Against the backdrop of approximately 25 to 30 million Americans living with a rare disease, and the vast majority of the roughly 10,000 known rare diseases still lacking an FDA-approved treatment, the plan outlines several important targets, including the following:
- an increase in the number of safe and effective treatments for rare disease patients
- an increase in the development and use of validated scientific and regulatory tools that meaningfully reduce development barriers and challenges in rare disease product development
- enhanced engagement with the rare disease community to leverage expertise and innovation, and promote more effective and informed rare disease drug development programs
- stronger coordination with internal, domestic, and international partners to facilitate greater consistency and coordination, thus increasing rare disease product development efficiency
- ensuring CDER has the capacity and tools to be equipped for innovation
“We want accountability and evaluation to be built into the plan’s structure, along with adaptability and efficiency.” – Elizabeth Hart, MD
BionewsHCP: The strategic plan includes performance indicators to track progress. Which measures will be most important in determining whether ARC is accelerating the development of safe and effective treatments, and how will that progress translate into benefits for patients?
Dr. Hart: The strategic plan is designed as a living document — one that establishes specific objectives and Key Performance Indicators (KPIs) for each of its three goals and that can add new KPIs as the ARC Program expands. That design choice reflects something important: We want accountability and evaluation to be built into the plan’s structure, along with adaptability and efficiency.
ARC’s phased maturity model (ie, establish and expand program infrastructure, refine program operations, achieve program impact) provides a structured framework to assess current capabilities, identify areas for improvement, set clear growth targets, and measure progress over time. This strategy supports ARC’s program expansion while enabling continuous improvement and aligned programmatic efforts across the ARC program. These efforts also ensure ARC is successful in working collaboratively with the rare disease community to increase the availability of safe and effective therapies that meaningfully improve patients’ lives.
“Mechanistic evidence, nonclinical data, pharmacodynamic findings, and clinical experience can be the evidentiary foundation for evaluating…a therapy targeting…a rare disease.” – Elizabeth Hart, MD
BionewsHCP: As understanding of rare disease biology advances, how are researchers changing the way they identify and prioritize treatment targets? Which approaches offer the greatest potential to move beyond symptom management toward modifying disease progression or addressing its underlying cause?
Dr. Hart: Our understanding of rare disease pathophysiology, including insights into specific genetic defects as the root biologic driver of disease, has led to increased development of targeted rare disease therapies. The agency’s regulatory approach has evolved alongside the science.
We are better positioned to apply targeted, context-specific regulatory considerations that reflect the biology of disease and drug mechanism of action, aimed at accelerating the development of safe and effective drugs for patients with rare diseases.
For instance, FDA’s February 2026 draft guidance on considerations for the use of plausible mechanism framework describes how strong mechanistic evidence, nonclinical data, pharmacodynamic findings, and clinical experience can be the evidentiary foundation for evaluating the safety and effectiveness of a therapy targeting the root genetic cause of a rare disease. This approach is outlined for diseases affecting very small patient populations, where traditional trial designs are not feasible.
“The small population affected by a rare disease presents additional considerations that must be addressed and calls for appropriate flexibility.” – Elizabeth Hart, MD
BionewsHCP: ARC’s strategic plan also emphasizes innovative trial designs, statistical approaches, natural history studies, and novel endpoints. Which of these approaches could have the greatest impact on generating meaningful evidence for diseases with small patient populations or limited established outcome measures?
Dr. Hart: It is the combination of these approaches and innovation, along with collaboration and input from patients and families, that can maximize outcomes for small populations. In rare disease drug development, there is no one-size-fits-all approach. Programs must be tailored to the context of use.
FDA recognizes that certain aspects of drug development that are feasible for common diseases may not be feasible for rare diseases and that development challenges are often greater with increasing rarity of the disease. For example, the small population affected by a rare disease presents additional considerations that must be addressed and calls for appropriate flexibility. The kind and quantity of data in each rare disease application will be different based on the unique considerations of each development program and must therefore be assessed on a case-by-case basis.
The ARC Program’s LEADER 3D suite of educational materials illustrates relevant regulatory considerations for rare disease drugs and biologics regulated by CDER and is designed to aid drug developers in navigating the challenges inherent to rare disease drug development.
BionewsHCP: How can researchers and clinicians determine whether a treatment’s biological effects — such as changes in a biomarker or protein production — are likely to translate into meaningful improvements in symptoms, function, or disease progression?
Dr. Hart: Ultimately, the goal of any treatment is to improve symptoms and outcomes that matter to patients. Endpoint selection is an important consideration in clinical trial design and can be particularly challenging in rare disease product development.
Biomarkers have multiple uses in rare disease drug development, including potentially supporting efficacy. When robust scientific evidence establishes that a biomarker reliably predicts a meaningful clinical outcome, it can serve as a validated surrogate endpoint (SE). For serious or life-threatening conditions with unmet medical needs, a reasonably likely surrogate endpoint (RLSE), can be used to predict clinical benefit for accelerated approval; the ultimate benefit reflecting how patients feel, function, or survive is confirmed after approval.
Determining whether there is adequate scientific evidence to support a biomarker as an RLSE depends on multiple factors, including the evidence supporting the magnitude and biologic plausibility of the relationship between the disease, the SE, and the specific clinical outcome the SE is intended to predict. It is important that the assay used to measure the biomarker has robust analytic validation to determine its reliability, accuracy, sensitivity, and specificity.
Stakeholders, including patient advocates, clinicians, and researchers, can engage with CDER through Critical Path Innovation Meetings (CPIM) to discuss knowledge gaps in drug development that are not product-specific. Clinicians and researchers can also develop biomarkers through CDER’s qualification program. Researchers and drug developers are encouraged to reach out to the appropriate CDER review division early and throughout their drug development program to discuss clinical trial design, endpoint selection, statistical analysis plans, as well as how and which elements of their development program will be used to demonstrate substantial evidence of effectiveness.
“Physicians play an important role in diagnosing and treating patients, and referring patients who are potentially eligible.” – Elizabeth Hart, MD
BionewsHCP: What should physicians across primary care and specialty practice understand about evaluating emerging rare disease therapies, identifying potentially eligible patients, and connecting them with appropriate treatment options or clinical trials?
Dr. Hart: Each stakeholder in rare disease drug development, including physicians, patients, and families, plays an important role. FDA recognizes that rare diseases are inherently rare, and that many rare diseases affect patients around the world. Physicians play an important role in diagnosing and treating patients, and referring patients who are potentially eligible for clinical trials and natural history studies.
Overall, the FDA is committed to facilitating the development of treatments for rare diseases and has developed numerous resources through the ARC program to support rare disease drug development.
See also, CDER’s Amy Comstock Rick, JD, on the Rare Disease Innovation Hub efforts.